Feverfew as a preventive treatment for migraine: A systematic review

Cephalalgia

Volumn 18, Issue 10, 1998, Pages 704-708

  Vogler, B K ^a   Pittler, M H ^a   Ernst, E ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Alternative medicine; Feverfew; Herbal medicine; Migraine; Tanacetum parthenium

Indexed keywords

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FLATULENCE; HEART PALPITATION; HUMAN; INDIGESTION; JOINT STIFFNESS; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PHYTOTHERAPY; RASH; TANACETUM PARTHENIUM;

HUMANS; MIGRAINE DISORDERS; PLANT EXTRACTS; PLANTS, MEDICINAL; RANDOMIZED CONTROLLED TRIALS; SESQUITERPENES; TANACETUM PARTHENIUM;

EID: 0032415628     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1998.1810704.x     Document Type: Article

References (30)

1. Fisher P, Ward A. Complementary medicine in Europe. Br Mod J 1994;309:107-11
2. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. N Engl J Med 1993;328:246-52
3. MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. Lancet 1996;347:569-73
4. Häusermann D. Wachsendes Vertrauen in Naturheilmittel. Dtsch Ärzteblatt 1997;94:1857-8
5. Astin JA. Why patients use alternative medicine. Results of a national study. J Am Med Assoc 1998;279:1548-53
6. Muller JL, Clauson KA. Pharmaceutical considerations of common herbal medicine. Am J Man Care 1997;3:1753-70
7. Knight D. Feverfew: chemistry and biological activity. Natural Product Reports 1995:271-6
8. Heptinstall S, White A, Williamson L, Mitchel JRA. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1985;i:1071-4
9. De Weerdt CJ, Bootsma HPR, Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1996;3:225-30
10. Jadad AK, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: Is blinding necessary? Controlled Clin Trials 1996;17:1-12
11. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 1985;291:569-73
12. Murphy JJ, Heptinstall S, Mitchell JRA. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;i:189-92
13. Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997;11:508-11
14. Kuritzky A, Elhacham Y, Yerushalmi Z, Hering R. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1994;44 Suppl 2:293P
15. Tfelt-Hansen P, Nielsen SL. Patient numbers needed in prophylactic migraine trials. Neuroepidemiology 1987;6: 214-9
16. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867-72
17. Ernst E, Pittler MH. Alternative therapy bias [Letter]. Nature 1997;385:480
18. Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralisation of sulphydryl groups. J Pharm Pharmacol 1987;39:459-65
19. Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 1988;40:743-5
20. Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukotrienes Med 1982;8:653-60
21. Awang DVC. Prescribing therapeutic feverfew (Tanacetum parthenium (L.) Schultz Bip., syn. Chrysanthemum parthenium (L.) Bernh.). Integrative Med 1998;1:11-3
22. Goadsby PJ. How do the currently used prophylactic agents work in migraine? Cephalalgia 1997;17:85-92
23. Brown AMG, Edwards CM, Davey MR, Power B, Lowe KC. Pharmacological activity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): assessment by inhibition of human polymorphonuclear leucocyte chemiluminescence in vitro. J Pharm Pharmacol 1997;49:558-61
24. Hendriks H, Bos R, Woerdenbag HJ. The essential oil of Tanacetum parthenium (L.) Schultz-Bip. Flavour Flagrance J 1996;11:367-71
25. Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 1997;350:1598-9
26. Brun J, Claustrat B, Saddier P, Chazot G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995;15:136-9
27. Anderson D, Jenkinson PC, Dewdney RS, Blowers SD, Johnson ES, Kadam NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and matched non-users. Human Toxicol 1988;7:145-52
28. Burry JN. Compositae dermatitis in South Australia: contact dermatitis from Chrysanthemum parthenium. Contact Dermatitis 1980;6:445
29. Hausen BM, Osmundsen PE. Contact allergy to parthenolide in Tanacetum parthenium (L.) Schultz-Bip. (feverfew, Asteraceae) and cross-reactions to related sesquiterpene lactone containing compositae species. Acta Derm Venereol 1983;63:308-14
30. Johnson ES. Patients who chew chrysanthemum leaves. MIMS Mag 1983;15 May: 32-35